PeptidePlaza
The Free Peptide Reference

Argireline

From PeptidePlaza, the free peptide reference · Entry #048 · Anti-Aging · Hand-curated entry · Editorial standards

Research warning. Cosmetic ingredient — not intended for injection or systemic use. Injecting a SNARE-interfering peptide is not a validated route and has no safety data; the compound was designed and assessed exclusively for topical application. Efficacy claims should be read against a genuine and unresolved skin-permeation problem.

Argireline (also known as Acetyl hexapeptide-8, Acetyl hexapeptide-3, Argireline, AH8) is a anti-aging research peptide. A six-residue mimic of the SNAP-25 N-terminus, designed to interfere with the same vesicle-fusion machinery botulinum toxin cleaves. The mechanism is real; the question is whether enough of it reaches the muscle.

Acetyl hexapeptide-8 (trade name Argireline) is a synthetic hexapeptide patterned on the N-terminal sequence of SNAP-25, a component of the SNARE complex that mediates fusion of acetylcholine vesicles with the presynaptic membrane at the neuromuscular junction. By competing with native SNAP-25 for incorporation into the SNARE complex, it destabilises complex formation and reduces catecholamine and acetylcholine release — mechanistically analogous to botulinum toxin, which cleaves SNAP-25 outright, though vastly less potent. Introduced as a topical cosmetic ingredient in the early 2000s, it is now among the most widely used "neurocosmetic" peptides, marketed for expression lines. Its real controversy is not mechanism but delivery: at roughly 889 Da and highly hydrophilic, it crosses the stratum corneum poorly, and whether meaningful concentrations reach neuromuscular junctions beneath the dermis remains genuinely contested. Published studies report reductions in wrinkle depth of roughly 10–30% over 4–8 weeks with 5–10% formulations — a real but modest effect that may owe as much to hydration and formulation as to SNARE interference. The Cosmetic Ingredient Review panel has assessed it as safe as used in cosmetics.

1 Mechanism of action

Mimics the N-terminal domain of SNAP-25 and competes for its position within the SNARE complex, destabilising complex assembly and reducing calcium-dependent vesicle fusion at the presynaptic terminal. Less neurotransmitter release means weaker muscle contraction and reduced dynamic expression lines. Contrast with botulinum toxin, which enzymatically cleaves SNAP-25 and acts with orders of magnitude greater potency.

Primary targets: SNARE complex / SNAP-25 (competitive interference)

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Reported benefits

  • Reduced wrinkle depth of ~10–30% in published topical studies
  • Non-invasive alternative to injectable neuromodulators
  • Assessed as safe in cosmetic use by the Cosmetic Ingredient Review panel
  • Excellent chemical stability in aqueous cosmetic formulations
  • No systemic neuromuscular effects at topical concentrations

2.2 Side effects

  • Mild skin irritation or erythema in sensitive individuals
  • Contact dermatitis (uncommon)
  • Tingling or transient tightness on application
  • Effects reverse completely on discontinuation

3 Chemical and physical properties

CAS number616204-22-9
Molar mass888.99 g/mol
Purity (typical)>98%
Half-lifeTopical — limited systemic absorption; local persistence measured in hours
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsSNARE complex / SNAP-25 (competitive interference)

3.1 Amino acid sequence

Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2

4 Research dosages

Topical cosmetic formulations: 5–10% aqueous solution applied once or twice daily. No validated injectable or systemic protocol exists.

Dosages are reported from published protocols for reference only. Research chemicals are not for human consumption.

5 Research studies (8)

  1. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy
    International Journal of Molecular Sciences (2025) · Review · N/A (review)
    Review of the permeation problem and efficacy evidence for acetyl hexapeptide-8 in topical formulations.
    Key finding: Efficacy is constrained principally by stratum corneum penetration; delivery enhancement, not peptide potency, is the limiting variable.
  2. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics
    International Journal of Toxicology (2025) · Review · N/A (safety assessment)
    Cosmetic Ingredient Review expert panel safety assessment of acetyl hexapeptide-8 in cosmetic formulations.
    Key finding: Assessed as safe in the present practices of use and concentration in cosmetics.
  3. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.
    International journal of molecular sciences (2025) · Review
    Biomimetic peptides represent a growing class of active ingredients in modern cosmeceuticals, designed to mimic the function of the naturally occurring peptides involved in skin homeostasis, repair, and...
  4. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics.
    International journal of toxicology (2025) · Preclinical
    The Expert Panel for Cosmetic Ingredient Safety (Panel) reviewed the safety of Acetyl Hexapeptide-8 Amide (synonymous with Acetyl Hexapeptide-8 (sans "Amide")) in cosmetic products; this ingredient is reported...
  5. Cosmeceuticals in photoaging: A review.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2024) · Systematic Review
    Topical cosmeceuticals like botanicals, peptides and hydroquinone can effectively treat photodamaged skin.
  6. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis.
    JMIR dermatology (2024) · Preclinical
    The increasing interest in acetyl hexapeptide-8 may be due to its cost-effectiveness and use as a botulinum neurotoxin alternative.
  7. Polydioxanone Bioactive Sutures-Acetyl Hexapeptide-8 (Argireline): An Intelligent System for Controlled Release in Facial Harmonization.
    Journal of cutaneous and aesthetic surgery (2023) · Preclinical
    The PDO thread system with Arg is an intelligent bioactive system useful in facial harmonization.
  8. Argireline: Needle-Free Botox as Analytical Challenge.
    Chemistry & biodiversity (2021) · Preclinical
    Argireline-containing cosmetics attract public interest due to their confirmed reduction of facial wrinkles.

6 Safety and risk profile

6.1 Regulatory status

Argireline is currently classified as Not approved. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety score: 90/100 — low concern. Derived from clinical data volume, known risks and regulatory status.

6.2 Contraindications

Conditions and populations in which use is contraindicated:

  • Known hypersensitivity to the peptide or formulation excipients
  • Application to broken or compromised skin
  • Neuromuscular disease (theoretical, if delivery is enhanced by microneedling or injection)
  • Pregnancy or lactation (precautionary for enhanced-delivery use)

6.3 Drug interactions

Drug or classInteractionRisk
Botulinum toxin injectionsOverlapping mechanism; no evidence of additive benefit and no combination safety data.Low
Retinoids (topical)Compromised barrier from retinoid use increases peptide penetration and irritation potential.Low
Chemical exfoliants (AHA/BHA)Altered stratum corneum changes absorption; may increase irritation.Low

6.4 Long-term risks

  • No evidence of cumulative toxicity in topical use
  • Theoretical neuromuscular effects if delivery is substantially enhanced
  • Effects are entirely non-durable — benefit ceases with use

6.5 Research best practices

  • Store lyophilised at −20 °C; aqueous solutions refrigerated and preserved
  • Formulate at pH 5–7 for stability; avoid strongly acidic or basic vehicles
  • Penetration enhancement is the rate-limiting variable — formulation matters more than concentration
  • Do not inject: the safety data covers topical application only
Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

7 Frequently asked questions

Is Argireline really "topical Botox"?
It shares a conceptual target — the SNARE machinery — but not the potency or the mode of action. Botulinum toxin is an enzyme that permanently cleaves SNAP-25 at picomolar concentrations after injection into the muscle; Argireline is a peptide that competes reversibly for complex assembly and must first traverse the stratum corneum. The marketing comparison overstates the reality substantially.
Does it actually penetrate the skin?
That is the central question. At ~889 Da and highly hydrophilic it is a poor candidate for passive diffusion through the stratum corneum. Formulation strategies — liposomes, penetration enhancers, microneedling — exist precisely because unaided penetration is inadequate.
What results do studies actually show?
Published work reports roughly 10–30% reduction in wrinkle depth over 4–8 weeks with 5–10% formulations. That is a real but modest effect, and studies are typically small, industry-sponsored and short.

8 References

  1. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. PubMed (2025). Zdrada-Nowak J, et al.. View source
  2. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. PubMed (2025). Johnson W, et al.. View source
  3. Cosmeceuticals in photoaging: A review. PubMed (2024). Chan LKW, et al.. View source
  4. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. PubMed (2024). Olsson SE, et al.. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Argireline.

AOD-9604metabolic

Shares mimics and release pharmacology

A modified C-terminal fragment of human growth hormone (amino acids 177-191) with a tyrosine substitution. Studied primarily for its lipolytic (fat-burning) effects without the growth-promoting activity of full-length hGH.

SS-31anti-aging

Shares complex and release pharmacology

A cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane by binding cardiolipin. Protects mitochondrial cristae structure and reduces oxidative stress without scavenging ROS directly.

Epitalonanti-aging

Shares reduced and expression pharmacology

A synthetic tetrapeptide derived from the pineal gland peptide Epithalamin. Studied extensively by Vladimir Khavinson for telomerase activation, circadian regulation, and life extension in animal models.

Gastrinmetabolic

Shares muscle and contraction pharmacology

Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.

Bradykininrecovery

Shares position and contrast pharmacology

Bradykinin is an endogenous human peptide involved in various physiological processes, including blood coagulation and inflammation.

Teriparatideapproved

Also anti-aging

The first drug that builds bone rather than merely slowing its loss — and it works only because it is given as a daily pulse. Continuous exposure to the same peptide destroys bone instead.

9 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.